Chemomab Therapeutics Ltd. (CMMB) is scheduled to make presentations at the Annual Congress of the European Association for the Study of the Liver in Barcelona, Spain, on May 30, 2026.
This clinical-stage biotechnology company is developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Its lead drug candidate is Nebokitug, a first-in-class dual activity monoclonal antibody that neutralizes CCL24, a soluble protein that helps drive the inflammatory and fibrotic pathways central to primary sclerosing cholangitis and other fibro-inflammatory diseases.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Prabha Kurup
For comments and feedback: contact editorial@rttnews.com